Aurobindo Pharma Subsidiary Clears US FDA Inspection with One Observation

Aurobindo Pharma announced that its subsidiary, Auro Peptides Limited, has successfully completed a routine inspection by the United States Food and Drug Administration (US FDA). The inspection, which took place from August 17th to 21st, 2026, at the peptide API manufacturing facility in Telangana, concluded with a single observation related to facility and equipment maintenance. Importantly, this observation does not concern data integrity or GMP compliance. Corrective actions were initiated during the inspection, and a formal response will be submitted within the stipulated timeline. This outcome underscores Aurobindo Pharma's commitment to high quality and compliance standards across its operations.